Catalyst
Slingshot members are tracking this event:
Aimmune (AIMT) Expects to Complete Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies in H2 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Occurred Source:
https://www.sec.gov/Archives/edgar/data/1631650/000156459016025333/aimt-ex991_22.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Palisade Trial, Complete Enrollment, H2 2016, Peanut Allergies
